U.S. News & World Report: Wegovy Helps Heart Failure Patients Lose Weight, Improve Symptoms

Weight-loss drugs like Wegovy can improve symptoms in heart failure patients, a new clinical trial shows.

Both men and women showed improved heart function after a year on semaglutide, the active ingredient in Ozempic and Wegovy, researchers report.

Women tended to lose more weight than men, on average about 9.6% of their body weight compared with 7.2% in men.

However, both genders experienced similar improvements regarding their heart health, researchers found. This could mean the drug might have heart benefits above and beyond helping people lose weight.

The results shed light on “the consistent benefits of semaglutide for women and men,” said senior researcher Dr. Mikhail Kosiborod, a cardiologist and vice president of research at Saint Luke's Mid America Heart Institute in Kansas City, Mo.

Read the full U.S. News & World Report article: Wegovy Helps Heart Failure Patients Lose Weight, Improve Symptoms

Related Content

Jun. 25, 2024

Cardiovascular Business: Semaglutide Improves Heart Failure Symptoms in Both Sexes—Weight Loss Greater in Women
Semaglutide improves symptoms in both men and women who present with heart failure. When it comes to weight loss, however, the drug appears to benefit women much more than men.
May. 31, 2024

KSHB: Are Weight-Loss Drugs the Future of Medicine? Here's What KC-Area Experts Had to Say
KSHB talked to Dr. Mikhail Kosiborod about the significant impact of new weight-loss drugs for those who need it most.
Apr. 8, 2024

MEDIA COVERAGE: Obesity Medication Proves Effective in Treating Patients with Obesity-Related Heart Failure and Type 2 Diabetes
A new study led by Dr. Mikhail Kosiborod found patients with obesity-related heart failure and type 2 diabetes had significant improvement in symptoms and physical limitations when taking semaglutide.